As of March 20, 2023, over 13 billion COVID-19 vaccine doses had been administered worldwide, with the United States accounting for almost 672 million of this total. This statistic shows the number of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country.

As of December 23, 2022, around 80 percent of the population of the United States had been given at least one dose of a COVID-19 vaccination. This statistic shows the percentage of population in select countries and territories worldwide that had received a COVID-19 vaccination as of December 23, 2022.

About Dataset: WHO COVID-19 Global Data

This dataset provides comprehensive information on the global COVID-19 pandemic as reported to the World Health Organization (WHO). The dataset is available in comma-separated values (CSV) format and includes the following fields:

Daily cases and deaths by date reported to WHO: WHO-COVID-19-global-data.csv

• Date_reported (Date): The date of reporting to WHO.
• Country_code (String): The ISO Alpha-2 country code.
• Country (String): The name of the country, territory, or area.
• WHO_region (String): The WHO regional office to which the country belongs. WHO Member States are grouped into six WHO regions, including AFRO (Regional Office for Africa), AMRO (Regional Office for the Americas), SEARO (Regional Office for South-East Asia), EURO (Regional Office for Europe), EMRO (Regional Office for the Eastern Mediterranean), and WPRO (Regional Office for the Western Pacific).
• New_cases (Integer): The number of new confirmed cases reported on a given day. This is calculated by subtracting the previous cumulative case count from the current cumulative case count.
• Cumulative_cases (Integer): The total cumulative confirmed cases reported to WHO up to the specified date.
• New_deaths (Integer): The number of new confirmed deaths reported on a given day. Similar to new cases, this is calculated by subtracting the previous cumulative death count from the current cumulative death count.- Cumulative_deaths (Integer): The total cumulative confirmed deaths reported to WHO up to the specified date.

In addition to the COVID-19 case and death data, this dataset also includes valuable information related to COVID-19 vaccinations. The vaccination data consists of the following fields:

Vaccination Data Fields: vaccination-data.csv

• COUNTRY (String): Country, territory, or area.
• ISO3 (String): ISO Alpha-3 country code.
• WHO_REGION (String): The WHO regional office to which the country belongs.
• DATA_SOURCE (String): Indicates the data source, which can be either "REPORTING" (Data reported by Member States or sourced from official reports) or "OWID" (Data sourced from Our World in Data COVID-19 Vaccinations).
• DATE_UPDATED (Date): Date of the last update.
• TOTAL_VACCINATIONS (Integer): Cumulative total vaccine doses administered.
• PERSONS_VACCINATED_1PLUS_DOSE (Decimal): Cumulative number of persons vaccinated with at least one dose.
• TOTAL_VACCINATIONS_PER100 (Integer): Cumulative total vaccine doses administered per 100 population.
• PERSONS_VACCINATED_1PLUS_DOSE_PER100 (Decimal): Cumulative persons vaccinated with at least one dose per 100 population.
• PERSONS_LAST_DOSE (Integer): Cumulative number of persons vaccinated with a complete primary series.
• PERSONS_LAST_DOSE_PER100 (Decimal): Cumulative number of persons vaccinated with a complete primary series per 100 population.
• VACCINES_USED (String): Combined short name of the vaccine in the format "Company - Product name."
• FIRST_VACCINE_DATE (Date): Date of the first vaccinations, equivalent to the start/launch date of the first vaccine administered in a country.
• NUMBER_VACCINES_TYPES_USED (Integer): Number of vaccine types used per country, territory, or area.
• PERSONS_BOOSTER_ADD_DOSE (Integer): Cumulative number of persons vaccinated with at least one booster or additional dose.
• PERSONS_BOOSTER_ADD_DOSE_PER100 (Decimal): Cumulative number of persons vaccinated with at least one booster or additional dose per 100 population.

In addition to the vaccination data, a separate dataset containing vaccination metadata is available, including information about vaccine names, product names, company names, authorization dates, start and end dates of vaccine rollout, and more.

Vaccination metadata Fields: vaccination-metadata.csv

• ISO3 (String): ISO Alpha-3 country code
• VACCINE_NAME (String): Combined short name of vaccine: "Company - Product name" (see below)
• PRODUCT_NAME (String): Name or label of vaccine product, or type of vaccine (if unnamed).
• COMPANY_NAME (String): Marketing authorization holder of vaccine product.
• FIRST_VACCINE_DATE (Date): Date of first vaccinations. Equivalent to start/launch date of the first vaccine administered in a country.
• AUTHORIZATION_DATE (Date): Date vaccine product was authorized for use in the country, territory, area.
• START_DATE (Date): Start/launch date of vaccination with vaccine type (excludes vaccinations during clinical trials).
• END_DATE (Date): End date of vaccine rollout
• COMMENT (String): Comments related to vaccine rollout
• DATA_SOURCE (String): Indicates data source - REPORTING: Data reported by Member States, or sourced from official re...

In 2021, COVID-19 vaccine Comirnaty produced by Biontech and Pfizer is expected to make 36 billion U.S. dollars in sales worldwide, while Moderna's mRNA-1273 vaccine is expected to make (15 to) 18 billon U.S. dollars. This statistic illustrates the forecasted sales of select major COVID-19 vaccines worldwide in 2021 and 2022.

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

Global Covid-19 Data

Global Covid-19 data on cases, deaths, vaccinations, and more

By Valtteri Kurkela [source]

About this dataset

The dataset is constantly updated and synced hourly to ensure up-to-date information. With over several columns available for analysis and exploration purposes, users can extract valuable insights from this extensive dataset.

Some of the key metrics covered in the dataset include:

1. Vaccinations: The dataset covers total vaccinations administered worldwide as well as breakdowns of people vaccinated per hundred people and fully vaccinated individuals per hundred people.

2. Testing & Positivity: Information on total tests conducted along with new tests conducted per thousand people is provided. Additionally, details on positive rate (percentage of positive Covid-19 tests out of all conducted) are included.

3. Hospital & ICU: Data on ICU patients and hospital patients are available along with corresponding figures normalized per million people. Weekly admissions to intensive care units and hospitals are also provided.

4. Confirmed Cases: The number of confirmed Covid-19 cases globally is captured in both absolute numbers as well as normalized values representing cases per million people.

5.Confirmed Deaths: Total confirmed deaths due to Covid-19 worldwide are provided with figures adjusted for population size (total deaths per million).

6.Reproduction Rate: The estimated reproduction rate (R) indicates the contagiousness of the virus within a particular country or region.

7.Policy Responses: Besides healthcare-related metrics, this comprehensive dataset includes policy responses implemented by countries or regions such as lockdown measures or travel restrictions.

8.Other Variables of InterestThe data encompasses various socioeconomic factors that may influence Covid-19 outcomes including population density,membership in a continent,gross domestic product(GDP)per capita;

For demographic factors: -Age Structure : percentage populations aged 65 and older,aged (70)older,median age -Gender-specific factors: Percentage of female smokers -Lifestyle-related factors: Diabetes prevalence rate and extreme poverty rate

1. Excess Mortality: The dataset further provides insights into excess mortality rates, indicating the percentage increase in deaths above the expected number based on historical data.

The dataset consists of numerous columns providing specific information for analysis, such as ISO code for countries/regions, location names,and units of measurement for different parameters.

Overall,this dataset serves as a valuable resource for researchers, analysts, and policymakers seeking to explore various aspects related to Covid-19

How to use the dataset

Introduction:

• Understanding the Basic Structure:

  • The dataset consists of various columns containing different data related to vaccinations, testing, hospitalization, cases, deaths, policy responses, and other key variables.
  • Each row represents data for a specific country or region at a certain point in time.

• Selecting Desired Columns:

  • Identify the specific columns that are relevant to your analysis or research needs.
  • Some important columns include population, total cases, total deaths, new cases per million people, and vaccination-related metrics.

• Filtering Data:

  • Use filters based on specific conditions such as date ranges or continents to focus on relevant subsets of data.
  • This can help you analyze trends over time or compare data between different regions.

• Analyzing Vaccination Metrics:

  • Explore variables like total_vaccinations, people_vaccinated, and people_fully_vaccinated to assess vaccination coverage in different countries.
  • Calculate metrics such as people_vaccinated_per_hundred or total_boosters_per_hundred for standardized comparisons across populations.

• Investigating Testing Information:

  • Examine columns such as total_tests, new_tests, and tests_per_case to understand testing efforts in various countries.
  • Calculate rates like tests_per_case to assess testing efficiency or identify changes in testing strategies over time.

• Exploring Hospitalization and ICU Data:

  • Analyze variables like hosp_patients, icu_patients, and hospital_beds_per_thousand to understand healthcare systems' strain.
  • Calculate rates like icu_patients_per_million or hosp_patients_per_million for cross-country comparisons.

• Assessing Covid-19 Cases and Deaths:

  • Analyze variables like total_cases, new_ca...

This is the data repository for the 2019 Novel Coronavirus cases as well as vaccination of covid 19 worldwide combined. This data includes columns such as:

country - Data representing that country, date - Data representing that date, total_cases - Total cases of that country till that date, total_deaths - Total deaths of that country till that date, daily_cases - Total cases of that country till that date, daily_deaths - Total deaths of that country till that date, fully_vaccinated - Fillu vaccinated people of that country till that date,
total_vaccinations - Total vaccination of that country till that date, total_boosters - Total boosters shot of that country till that date,
daily_vaccinations - Daily vaccinations shots of that country till that date, daily_people_vaccinated - Daily people vaccinated of that country till that date,

The donation and sale of vaccines are diplomatic tools that have impact well beyond health policies. May Chinese Covid-related vaccine diplomacy be understood beyond reactive terms vis-à-vis power disputes with the West, in particularly the United States? We then scrutinize the drivers of China’s vaccine diplomacy, assessing whether Beijing privileged the expansion of its diplomatic leverage in the Global South. By employing logit and tobit models in the analysis of a cross-sectional dataset covering 213 countries, we examine the probability of countries receiving vaccines from China. We find that low-income states, in particular, and middle-income ones and those with more Covid deaths were more likely to receive vaccines through either donations or purchases. For donations, states that integrate the Belt and Road Initiative (BRI) and/or oppose the United States at the United Nations General Assembly (UNGA) were also privileged. China’s vaccine diplomacy has therefore a twofold purpose. First, the expansion of the country’s soft power in the Global South. Second, the consolidation of the BRI bilateral ties and an anti-US allied network. Hence, current global health initiatives cannot be detached from debates on the contestation of the liberal international order (LIO) and China’s dual role as a responsible stakeholder and most successful emerging power that has the potential to challenge American hegemony. Moreover, the findings also suggest that bilateral donor-recipient flows may be less politicized than what prior works on development aid and health diplomacy have claimed.

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in vacc

How many people have received a coronavirus vaccine?

Tracking COVID-19 vaccination rates is crucial to understand the scale of protection against the virus, and how this is distributed across the global population.

A global, aggregated database on COVID-19 vaccination rates is essential to monitor progress, but it is unfortunately not yet available. This dataset provides the last weekly update of vaccination rates.

Last update

June 2021

Content

Colums description: 1. iso_code: ISO 3166-1 alpha-3 – three-letter country codes 2. continent: Continent of the geographical location 3. location: Geographical location 4. date: Date of observation 5. total_cases: Total confirmed cases of COVID-19 6. new_cases: New confirmed cases of COVID-19 7. new_cases_smoothed: New confirmed cases of COVID-19 (7-day smoothed) 8. total_deaths: Total deaths attributed to COVID-19 9. new_deaths: New deaths attributed to COVID-19 10. new_deaths_smoothed: New deaths attributed to COVID-19 (7-day smoothed) 11. total_cases_per_million: Total confirmed cases of COVID-19 per 1,000,000 people 12. new_cases_per_million: New confirmed cases of COVID-19 per 1,000,000 people 13. new_cases_smoothed_per_million: New confirmed cases of COVID-19 (7-day smoothed) per 1,000,000 people 14. total_deaths_per_million: Total deaths attributed to COVID-19 per 1,000,000 people 15. new_deaths_per_million: New deaths attributed to COVID-19 per 1,000,000 people 16. new_deaths_smoothed_per_million: New deaths attributed to COVID-19 (7-day smoothed) per 1,000,000 people 17. reproduction_rate: Real-time estimate of the effective reproduction rate (R) of COVID-19. See http://trackingr-env.eba-9muars8y.us-east-2.elasticbeanstalk.com/FAQ 18. icu_patients: Number of COVID-19 patients in intensive care units (ICUs) on a given day 19. icu_patients_per_million: Number of COVID-19 patients in intensive care units (ICUs) on a given day per 1,000,000 people 20. hosp_patients: Number of COVID-19 patients in hospital on a given day 21. hosp_patients_per_million: Number of COVID-19 patients in hospital on a given day per 1,000,000 people 22. weekly_icu_admissions: Number of COVID-19 patients newly admitted to intensive care units (ICUs) in a given week 23. weekly_icu_admissions_per_million: Number of COVID-19 patients newly admitted to intensive care units (ICUs) in a given week per 1,000,000 people 24. weekly_hosp_admissions: Number of COVID-19 patients newly admitted to hospitals in a given week 25. weekly_hosp_admissions_per_million: Number of COVID-19 patients newly admitted to hospitals in a given week per 1,000,000 people 26. total_tests: Total tests for COVID-19 27. new_tests: New tests for COVID-19 28. new_tests_smoothed: New tests for COVID-19 (7-day smoothed). For countries that don't report testing data on a daily basis, we assume that testing changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window 29. total_tests_per_thousand: Total tests for COVID-19 per 1,000 people 30. new_tests_per_thousand: New tests for COVID-19 per 1,000 people 31. new_tests_smoothed_per_thousand: New tests for COVID-19 (7-day smoothed) per 1,000 people 32. tests_per_case: Tests conducted per new confirmed case of COVID-19, given as a rolling 7-day average (this is the inverse of positive_rate) 33. positive_rate: The share of COVID-19 tests that are positive, given as a rolling 7-day average (this is the inverse of tests_per_case) 34. tests_units: Units used by the location to report its testing data 35. total_vaccinations: Number of COVID-19 vaccination doses administered 36. total_vaccinations_per_hundred: Number of COVID-19 vaccination doses administered per 100 people 37. stringency_index: Government Response Stringency Index: composite measure based on 9 response indicators including school closures, workplace closures, and travel bans, rescaled to a value from 0 to 100 (100 = strictest response) 38. population: Population in 2020 39. population_density: Number of people divided by land area, measured in square kilometers, most recent year available 40. median_age: Median age of the population, UN projection for 2020 41. aged_65_older: Share of the population that is 65 years and older, most recent year available 42. aged_70_older: Share of the population that is 70 years and older in 2015 43. gdp_per_capita: Gross domestic product at purchasing power parity (constant 2011 international dollars), most recent year available 44. extreme_poverty: Share of the population living in extreme poverty, most recent year available since 2010 45. cardiovasc_death_rate: Death rate from cardiovascular disease in 2017 (annual number of deaths per 100,000 people) 46. diabetes_prevalence: Diabetes prevalence (% of population aged 20 to 79) in 2017 47. female...

Approved COVID-19 Vaccines Market Outlook

The global market size for approved COVID-19 vaccines stood at approximately USD 45 billion in 2023 and is projected to reach around USD 78 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This substantial growth is primarily driven by continuous advancements in vaccine technology, increasing global vaccination drives, and the emergence of new variants necessitating booster doses.

One of the primary growth factors for the approved COVID-19 vaccines market is the ongoing need for booster vaccinations. As new variants of the virus emerge, vaccine manufacturers are continuously enhancing existing vaccines to tackle these variants effectively. This continuous innovation ensures sustained demand for updated vaccines, thereby propelling market growth. Additionally, governments worldwide are investing heavily in vaccination programs to achieve herd immunity, further boosting market size. Initiatives like COVAX, which aim to provide equitable vaccine access, are also significant contributors to market expansion.

Another crucial factor driving market growth is the increased awareness and acceptance of vaccines among the global population. Intensive public health campaigns and educational movements have led to a higher acceptance rate of vaccines, reducing vaccine hesitancy. This trend is particularly significant in emerging economies where initial vaccine skepticism was high. The successful roll-out of initial vaccine doses has built public confidence, thereby increasing the uptake of booster doses and new vaccine variants.

The collaboration between pharmaceutical companies and governments has also played a pivotal role in the growth of the COVID-19 vaccines market. Strategic partnerships for vaccine production, distribution, and administration have streamlined the supply chain, making vaccines more accessible to the public. These collaborations have also facilitated bulk purchasing agreements, which have provided cost advantages and enhanced market penetration across various regions. Moreover, the establishment of new manufacturing facilities and the expansion of existing ones have significantly accelerated vaccine production capabilities.

The development of the COVID-19 RNA Vaccine has been a groundbreaking advancement in the fight against the pandemic. Unlike traditional vaccines, RNA vaccines work by introducing a small piece of genetic material from the virus into the body, prompting an immune response without using a live virus. This innovative approach has allowed for rapid development and deployment, significantly contributing to the global vaccination efforts. The flexibility of RNA technology also enables quick updates to the vaccine to address new variants, ensuring continued protection as the virus evolves. This adaptability has made RNA vaccines a crucial tool in achieving widespread immunity and controlling the spread of COVID-19.

Regionally, North America leads the market due to its advanced healthcare infrastructure and early adoption of vaccination programs. Europe follows closely, with significant contributions from countries like Germany, France, and the UK. The Asia Pacific region is witnessing rapid growth, driven by substantial investments in healthcare infrastructure and large-scale vaccination drives in countries like India and China. Meanwhile, Latin America and the Middle East & Africa are gradually catching up, supported by international aid and improving healthcare systems. The regional diversity ensures a balanced growth outlook for the global market.

Vaccine Type Analysis

The market for approved COVID-19 vaccines is segmented into various types, including mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have gained significant traction due to their high efficacy rates and the rapid speed of development. The flexibility of mRNA technology to adapt swiftly to new variants has positioned them as a frontrunner in the market. This segment is expected to continue its dominance, supported by ongoing research and development activities aimed at enhancing vaccine formulations and delivery mechanisms.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. AstraZeneca and Johnson & Johnson are key players in t

COVID-19 Vaccines-Production Capacity & Development Timeline Market Outlook

According to our latest research, the global COVID-19 vaccines market size reached USD 40.2 billion in 2024, reflecting a significant contraction from the pandemic’s peak but remaining a critical segment of the global biopharmaceutical industry. The market is projected to grow at a CAGR of 3.7% from 2025 to 2033, reaching a forecasted value of USD 56.7 billion by 2033. This growth is primarily driven by the ongoing need for booster vaccinations, the emergence of new viral variants, and sustained investments in vaccine research and production capabilities worldwide. The market’s resilience is further supported by government procurement programs and the expansion of vaccine access in emerging economies.

The evolution of the COVID-19 vaccines market is shaped by several growth factors, notably the persistent circulation of SARS-CoV-2 and the continuous emergence of new variants that challenge existing immunity levels. Governments and health organizations worldwide remain vigilant, prioritizing the development and distribution of updated vaccines to counter variant-driven outbreaks. The introduction of bivalent and multivalent vaccines, designed to offer protection against multiple strains, has spurred ongoing demand. Furthermore, the increasing reliance on annual or biannual booster doses for vulnerable populations, such as the elderly and immunocompromised individuals, ensures a steady baseline for vaccine consumption. The integration of COVID-19 vaccination into routine immunization schedules is also anticipated to contribute to market stability over the forecast period.

Another key driver is the remarkable progress in vaccine technology, particularly the rapid advancement and deployment of mRNA vaccine platforms. The success of mRNA vaccines has not only revolutionized the response to COVID-19 but has also accelerated research and development for other infectious diseases. This technological leap has encouraged investments in flexible manufacturing infrastructure, enabling faster adaptation to emerging threats and enhancing global production capacity. Additionally, partnerships between pharmaceutical companies, governments, and contract manufacturing organizations (CMOs) have optimized supply chains, improved scalability, and facilitated technology transfer to developing regions. These collaborative efforts are essential for maintaining readiness against future pandemics and for addressing ongoing global health challenges.

Market growth is further bolstered by proactive government policies and international collaborations aimed at ensuring equitable vaccine distribution. Initiatives such as COVAX and bilateral agreements have played a crucial role in expanding vaccine access to low- and middle-income countries, thereby stimulating demand and supporting market expansion. The increasing participation of private procurement channels, including hospitals, clinics, and pharmacies, has diversified distribution networks and improved accessibility for broader populations. Moreover, the push for localized manufacturing and regulatory harmonization is streamlining vaccine approval processes and reducing dependency on a limited number of global suppliers. These trends collectively underpin the sustained growth trajectory of the COVID-19 vaccines market.

Regionally, North America and Europe continue to dominate the COVID-19 vaccines market, accounting for the largest shares due to robust healthcare infrastructure, high vaccination rates, and substantial government funding. However, the Asia Pacific region is exhibiting the fastest growth, driven by large-scale immunization campaigns, expanding manufacturing capabilities, and rising awareness about the importance of vaccination. Countries such as China and India are emerging as significant players in both vaccine production and consumption, supported by favorable policy frameworks and increasing investments in biotechnology. Latin America and the Middle East & Africa are also witnessing gradual improvements in vaccine coverage, although challenges related to infrastructure and affordability persist. Overall, the regional dynamics are expected to evolve as global efforts intensify to achieve comprehensive vaccine coverage and pandemic preparedness.

COVID-19 Vaccines Market provides Information about the key drivers and opportunities Key players BioNtech, Pfizer, Sanofi, Moderna, CureVac, Novartis.

As of February 2022, the latest COVID-19 vaccine by Sanofi/GlaxoSmithKline showed a 77 percent efficacy against the Delta variant of the coronavirus. This statistic illustrates the comparison of select COVID-19 vaccines worldwide, by their efficacy against the Delta variant.

State-by-state data on United States COVID-19 vaccinations data

Acknowledgement and License

All data are produced by Our World in Data are completely open access under the Creative Commons BY license. You have the permission to use, distribute, and reproduce these in any medium, provided the source and authors are credited. In the case of our vaccination dataset, please give the following citation:

Mathieu, E., Ritchie, H., Ortiz-Ospina, E. et al. A global database of COVID-19 vaccinations. Nat Hum Behav (2021). https://doi.org/10.1038/s41562-021-01122-8

Data Set Column Details

location : name of the state or federal entity. date: date of the observation. total vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. total vaccinations per hundred: total vaccinations per 100 people in the total population of the state. daily vaccinations raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily vaccinations instead. daily vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here. daily vaccinations per million: daily vaccinations per 1,000,000 people in the total population of the state. people vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. people vaccinated per hundred: people vaccinated per 100 people in the total population of the state. people fully vaccinated: total number of people who received all doses prescribed by the initial vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. people fully vaccinated per hundred: people fully vaccinated per 100 people in the total population of the state. total distributed: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System. total distributed per hundred: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System per 100 people in the total population of the state. share doses used: share of vaccination doses administered among those recorded as shipped in CDC's Vaccine Tracking System. total boosters: total number of COVID-19 vaccination booster doses administered (doses administered beyond the number prescribed by the initial vaccination protocol) total boosters per hundred: total boosters per 100 people in the total population.

Time Span

20th Dec 2020 to 28th Dec 2022

The global vaccine market, including COVID-19 vaccines, is a dynamic and rapidly evolving sector. With a 2025 market size of $58,060 million and a projected Compound Annual Growth Rate (CAGR) of 3.7% from 2025 to 2033, significant growth is anticipated. This expansion is driven by several factors, including rising prevalence of vaccine-preventable diseases, increasing government initiatives promoting vaccination programs, and advancements in vaccine technology leading to the development of more effective and safer vaccines. The COVID-19 pandemic significantly accelerated vaccine development and deployment, boosting market growth and highlighting the crucial role of vaccines in public health. However, challenges remain, including vaccine hesitancy, the high cost of vaccine development and distribution, and the need for continuous research and development to combat emerging infectious diseases and adapt to evolving viral strains. The market is highly competitive, with major players like Pfizer, Sanofi, AstraZeneca, and several prominent Chinese and Indian manufacturers vying for market share. Future growth will likely be influenced by the success of new vaccine candidates, the effectiveness of ongoing vaccination campaigns, and the emergence of new pandemic threats. The market is segmented based on vaccine type (live attenuated, inactivated, etc.), disease indication (influenza, measles, COVID-19, etc.), and route of administration. Geographical variations in vaccination rates and healthcare infrastructure will also influence regional market performance. The competitive landscape is characterized by a mix of established pharmaceutical giants and emerging biotechnology companies. Strategic partnerships, mergers and acquisitions, and continuous innovation are shaping the market dynamics. The increasing focus on personalized medicine and the development of next-generation vaccines, such as mRNA vaccines and gene-based vaccines, offer significant growth opportunities. However, regulatory hurdles and the stringent safety requirements associated with vaccine development pose significant challenges. To further fuel growth, companies are investing heavily in R&D to develop novel vaccines with improved efficacy, safety profiles, and ease of administration. This includes advancements in delivery systems like needle-free options and the exploration of combination vaccines to reduce the number of injections needed. Furthermore, global collaborations and investments in vaccine manufacturing capacity are crucial to ensure equitable access to vaccines worldwide.

Data From Our World in Data.

Universal Coronavirus Vaccines Market Outlook

As per our latest research, the global Universal Coronavirus Vaccines market size was valued at USD 1.27 billion in 2024 and is projected to reach USD 7.89 billion by 2033, growing at a robust CAGR of 22.1% during the forecast period. The market’s rapid expansion is driven by the urgent need for broad-spectrum vaccines capable of addressing current and future coronavirus strains, heightened by the ongoing threat of emerging variants and pandemic preparedness initiatives worldwide.

The primary growth factor propelling the Universal Coronavirus Vaccines market is the persistent evolution and mutation of coronaviruses, including SARS-CoV-2 and its variants of concern. Traditional vaccines, while effective, often require updates to address new mutations, leading to a continuous cycle of vaccine development and deployment. In contrast, universal coronavirus vaccines are designed to elicit broad immune responses against conserved viral elements, offering protection against a wide array of coronavirus strains. This scientific innovation is attracting significant investments from both public and private sectors, with governments and global health organizations prioritizing pandemic readiness and long-term immunity solutions. The accelerated pace of research and clinical trials, supported by advanced platforms such as mRNA and viral vectors, is further fueling market growth.

Another significant driver for the Universal Coronavirus Vaccines market is the increasing collaboration among pharmaceutical companies, research institutes, and regulatory agencies. The COVID-19 pandemic underscored the necessity of swift, coordinated responses to emerging infectious diseases, leading to unprecedented partnerships and funding. These collaborations have not only expedited vaccine candidate development but have also established new regulatory pathways for rapid approval and deployment. Moreover, the global emphasis on equitable vaccine access is encouraging the development of vaccines that are effective across diverse populations, including adults, pediatrics, and geriatrics. This inclusive approach is expanding the addressable market and ensuring that universal coronavirus vaccines become a cornerstone of global immunization strategies.

Technological advancements in vaccine platforms are also playing a crucial role in the growth of the Universal Coronavirus Vaccines market. Innovations such as next-generation protein subunits, self-amplifying mRNA, and DNA-based vaccines are enabling the design of candidates with enhanced safety profiles, stability, and immunogenicity. These platforms allow for rapid adaptation to new viral threats and facilitate large-scale manufacturing and distribution. Furthermore, the integration of artificial intelligence and bioinformatics in vaccine design is accelerating the identification of conserved viral targets, optimizing antigen selection, and streamlining preclinical and clinical evaluations. As a result, the Universal Coronavirus Vaccines market is witnessing a wave of novel candidates entering the pipeline, promising to redefine the landscape of infectious disease prevention.

From a regional perspective, North America currently dominates the Universal Coronavirus Vaccines market, accounting for the largest share due to its advanced healthcare infrastructure, substantial R&D investments, and proactive government initiatives. Europe follows closely, benefiting from strong public health systems and collaborative research networks. The Asia Pacific region, however, is poised for the fastest growth, driven by increasing healthcare expenditures, rising awareness about pandemic preparedness, and expanding vaccine manufacturing capabilities. Latin America and the Middle East & Africa are also witnessing growing interest, supported by international funding and efforts to improve vaccine accessibility. As countries across all regions prioritize pandemic resilience, the Universal Coronavirus Vaccines market is set for sustained expansion in the coming years.

Vaccine Type Analysis

The Universal Coronavirus Vaccines market by vaccine type is segmented into Protein Subunit Vaccines, Viral Vector Vaccines, mRNA Vaccines, DNA Vaccines, and Others. Among these, mRNA vaccines have gained significant traction due to their proven efficacy, rapid development timelines, and adaptability to emerging viral threats. The success of mRNA-based COVID-19 vaccines ha

Regarding all Vaccination Data The date of Last Update is 4/21/2023. Additionally on 4/27/2023 several COVID-19 datasets were retired and no longer included in public COVID-19 data dissemination. See this link for more information https://imap.maryland.gov/pages/covid-data Summary The cumulative number of COVID-19 vaccinations percent age group population: 16-17; 18-49; 50-64; 65 Plus. Description COVID-19 - Vaccination Percent Age Group Population data layer is a collection of COVID-19 vaccinations that have been reported each day into ImmuNet. COVID-19 is a disease caused by a respiratory virus first identified in Wuhan, Hubei Province, China in December 2019. COVID-19 is a new virus that hasn't caused illness in humans before. Worldwide, COVID-19 has resulted in thousands of infections, causing illness and in some cases death. Cases have spread to countries throughout the world, with more cases reported daily. The Maryland Department of Health reports daily on COVID-19 cases by county. Terms of Use The Spatial Data, and the information therein, (collectively the Data) is provided as is without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata. This map is for planning purposes only. MEMA does not guarantee the accuracy of any forecast or predictive elements.

Due to widespread Covid vaccination rates, the global trade in vaccines reached $42.5B, the highest level ever. Belgium topped the country rankings by the value of exports this year, followed by Germany and the U.S. Growing global demand stimulates the rapid expansion of Covid vaccine production facilities in the EU.